Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis

Table 1

Characteristics of the included studies on PD-L1 status predicting the prognosis in UC patients after cystectomy.

Study	Boorjian et al. (2008) [4]	Wang et al. (2009) [18]	Xylinas et al. (2014) [19]
Country	USA	China	USA
Study interval	1990-1994	2000-2002	1988-2003
Age (years)	69 (37-90)	62 (42-78)	66 (61-72)
Male/female	259/59	40/10	244/58
Management	RC	RC	RC
PD-L1 expression	Tumour cells	Tumour cells	Tumour cells
Detection method	IHC	IHC	IHC
Cut-off value	5%	10%	5%
Follow-up (mons.)	164 (1-210)	28 (6-52)	120 (78-125)
Clinical outcomes	Receipt of BCG, tumour stage, TIL	Tumour grade, tumour stage, recurrent UC	None
All UC patients
PD-L1+	12.4%	72.0%	25.2%
PD-L1+/-	39/275	36/14	76/226
OS, HR(95% CI)	1.06(0.71-1.58)	2.24(1.16-4.38)	0.98(0.73-1.31)
value	0.88	0.01	0.79
CSS, HR(95% CI)	0.82(0.42-1.63)	na	0.79(0.53-1.61)
value	0.23	na	0.58
DFS, HR(95% CI)	0.83(0.43-1.58)	na	0.74(0.50-1.11)
value	0.15	na	0.56
Organ-confined disease		na
PD-L1+	16.2%	na	25.0%
PD-L1+/-	27/140	na	24/72
OS, HR(95% CI)	2.18(1.26-3.77)	na	1.93(1.09-3.43)
value	0.02	na	0.005
CSS, HR(95% CI)	1.59(0.56-4.49)	na	1.21(0.47-3.13)
value	0.68	na	0.38
DFS, HR(95% CI)	1.24(0.44-3.45)	na	1.27(0.50-3.26)
value	0.62	na	0.69

UC: urothelial carcinoma; PD-L1: programmed death-ligand 1; +/-: positive/negative; RC: radical cystectomy; TIL: tumour-inflating lymphocyte; IHC: immunohistochemistry; BCG: Bacillus Calmette-Guerin; OS: overall survival; CSS: cancer-specific survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; na: data not available. No association of PD-L1 expression with clinicopathologic features.